Ratings Ipca Laboratories Limited

Equities

IPCALAB

INE571A01038

Market Closed - NSE India S.E. Other stock markets 05:19:10 14/05/2024 pm IST			5-day change	1st Jan Change
1,290 ^INR	-0.64%		-0.26%	+15.88%

29/03	Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director	CI
29/03	Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.65 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 4.49 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
IPCA LABORATORIES LIMITED	+15.88%	3.94B	C+
ELI LILLY AND COMPANY	+29.98%	682B	C+
NOVO NORDISK A/S	+32.39%	586B	B
JOHNSON & JOHNSON	-3.52%	364B	C+
MERCK & CO., INC.	+18.59%	327B	B-
ABBVIE INC.	+4.07%	285B	C+
ASTRAZENECA PLC	+16.50%	240B	B+
NOVARTIS AG	+9.56%	209B	B-
ROCHE HOLDING AG	-9.04%	203B	A+
AMGEN INC.	+7.09%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes